Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208702 · ClinicalTrials.gov registry record · Phase 4
Thyroid Medication and Antidepressants for Treating Major Depression
A Phase 4 study of Major Depression, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
- 1
- Study location
NCT00208702 is a Phase 4 study of Major Depression that has completed, run by Emory University. The registered enrollment target is 153 participants, below the 322-participant average among 28 other Major Depression trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00208702, a Phase 4 study of Major Depression, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sertraline
- DRUG Triiodothyronine
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 1996-09 |
| Est. Completion | 2003-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208702
The ClinicalTrials.gov registry entry for NCT00208702 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 28 other Major Depression trials with a reported enrollment target (52% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00208702 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00208702 about?
NCT00208702 is a clinical study titled "Thyroid Medication and Antidepressants for Treating Major Depression". This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).
What is the current status of trial NCT00208702?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 1996-09. Estimated completion is 2003-07.
What conditions does trial NCT00208702 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT00208702?
The interventions under investigation include: Placebo (OTHER), Sertraline (DRUG), Triiodothyronine (DRUG).
Who is sponsoring clinical trial NCT00208702?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00208702 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.